Xenon Pharmaceuticals Inc. (XENE)
- Sector
- Biotechnology
- Last price
- $34.42
- As of
Kresmion compiles this page from XENE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Xenon Pharmaceuticals Inc. (XENE): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
See the full XENE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for XENE on one page. Preview it with sample data, then open it live with a free account.
Preview the XENE dossierActive signals for XENE
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 82% of XENE (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +2888% to XENE (2026Q2)
- highCONSENSUS_BUY
4 tracked funds increased XENE this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +1302% to XENE (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +87% to XENE (2026Q2)
FREE, NO ACCOUNT
Every signal on XENE, as it fires
You are seeing 5 of 11 signals recorded on XENE since 2026-05-26.
The five above all landed on 2026-08-16. The other 6 were recorded on 2 other days. 8 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in XENE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 98420N105 · 2026Q2 | $99.2M | 0.07% | , |
| CITADEL ADVISORS LLCCUSIP 98420N105 · 2026Q2 | $84.6M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 98420N105 · 2026Q2 | $22.7M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 98420N105 · 2026Q2 | $13.5M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 98420N105 · 2026Q2 | $11.3M | 0.02% | , |
| Point72 Asset Management, L.P.CUSIP 98420N105 · 2026Q2 | $7.9M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, XENE
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
XENE against its peers
XENE's operating margin of -4974.3% ranks in the 15th percentile of 16 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | XENE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 7.5M USD | 179M USD | 24 | 18 |
| Operating margin | -4974.3% | -61.5% | 15 | 16 |
| Net margin | -4612.1% | -45.2% | 15 | 16 |
| Return on equity | -59.5% | -26.9% | 14 | 24 |
| 1 year | -13.9% | 33.3% | 13 | 19 |
Peers (24): IDYA, LEGN, VKTX, VCYT, ACAD, GRTX, ARQT, CELC, TLX, CPRX, RLAY, DNLI, DYN, TNGX, RCUS, ELVN, EWTX, ZLAB, PGEN, DNTH, ATAI, BEAM, MBX, TVTX. Left out: PBLS (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (XENE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow XENE on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to XENE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.